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ABSTRACT
ASSOCIATION OF FOLLICLE-STIMULATING HORMONE AND DEPRESSION
AND DEPRESSIVE SYMPTOMS IN OLDER POSTMENOPAUSAL WOMEN
MAY 2018
DANA FRITZ, B.S., UNIVERSITY OF CALIFORNIA, DAVIS
M.S., UNIVERSITY OF MASSACHUSETTS, AMHERST
Directed by: Professor Elizabeth R. Bertone-Johnson

Worldwide, between 5 and 18% of postmenopausal women experience
depression.1-3 While the associations of estrogens with depression have been researched
extensively, relations with other postmenopausal hormones remain unclear. We evaluated
the association of follicle stimulating hormone (FSH) levels with prevalent depression the
Kuopio Ischaemic Heart Disease Risk Factor Study (n = 588). Study participants were
postmenopausal women aged 53 to 73 years and not using hormone therapy at enrollment
(1998-2001). FSH was measured by radioimmuno-assays. Depression symptoms were
measured using a scale based on DSM-III criteria (score range = 0-12), with a score ≥5
indicative of probable depression. We assessed the relation of FSH levels with depression
in multivariable linear and logistic models adjusting for age, body mass index, estradiol,
antidepressant use, and other factors, and evaluated effect modification by age. In
adjusted analyses of all participants, higher FSH levels were associated with lower
prevalence of depression (OR comparing ≥50 vs <50 IU/L = 0.50, P = 0.02). Each 10unit increase in FSH was associated with a 17% lower prevalence of depression (95% CI
0.70-0.99). Regression coefficients for Quartiles (Q) 2-4 vs. Q1 of FSH were 0.208, -
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0.170, -0.472, respectively (P = 0.14). Associations were mainly observed in older
women (aged 64-73 years). In this group, the OR of prevalent depression was 0.47 (P =
0.05) compared to an OR of 0.57 (P = 0.25) in the younger group (aged 53-63).
Additionally, in this group, each 10-unit increase in FSH was associated with a 26%
lower prevalence of depression (95% confidence interval: 0.57-0.95). Furthermore, FSH
levels were inversely associated with symptom score in older women (regression
coefficients for Q2-4 vs. Q1: -0.35, -0.95, -1.37, respectively; P = 0.02). Higher FSH
levels in older postmenopausal women were associated with lower prevalence of
depression and depressive symptoms, independent of estradiol, adiposity measures, and
other factors. Further research is warranted to evaluate mechanisms underlying these
associations, including effects of FSH on immune function.
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CHAPTER I
INTRODUCTION
Depression is often not recognized and undertreated in developed and developing
countries worldwide. Depression contributes to disease burden often leading to or
exacerbating conditions such as cardiovascular disease, type 2 diabetes, arthritis, and
cancer.4,5 Depression also affects economic well-being, costing the United States $210.5
billion per year in direct and indirect costs.6 Of these costs, approximately $99 million are
directly attributable to depression. Established risk factors for depression include history
of depression (self or familial), major life changes, certain illnesses, and the use of certain
medications (e.g., isotretinoin, rimonabant, and corticosteroids).7,8 The prevalence of
depression is higher in women than men across all stages of life. In 2010, the global
prevalence of depression was 5.5% in women and 3.2% in men.9 This trend is visible
throughout populations worldwide independent of race, education, diet, and other
potential confounding factors suggesting that there may be biological differences due to
sex.
The prevalence of depression in postmenopausal women is estimated to be
between 5 and 18%.1-3 While various external factors contribute to the onset of
depression, internal factors should not be ignored. Hormonal changes that occur during
the menopausal transition may also contribute to depression in postmenopausal women.
When women go through the menopausal transition, they experience a rise in folliclestimulating hormone levels and a drop in estradiol levels.10-12 This fluctuation in
hormonal levels is associated with an increased incidence of depression in
perimenopausal women compared to premenopausal women.13 After menopause, the
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rate of change in hormone levels decreases substantially (FSH and estrogen levels slowly
decline), but prevalence of depression still remains a major health concern.
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CHAPTER II
PHYSIOLOGY OF FOLLICLE STIMULATING HORMONE AND DEPRESSION
Follicle stimulating hormone, or FSH, is one of two gonadotropic hormones, the
other being luteinizing hormone (LH). Prior to menopause, FSH is primarily responsible
for recruiting immature follicles to reach maturation so that an egg is released during
ovulation.14 Gonadotropin-releasing hormone (GnRH), which is released from the
hypothalamus, stimulates the production of FSH and LH in the pituitary gland.15,16 FSH
and LH travel to the ovary via the bloodstream stimulating follicular growth and
ovulation, as well as estrogen production. Estrogen then travels back to the brain to slow
the release of GnRH and, therefore, FSH through a process called negative feedback.
Activins A, B, and AB stimulate the secretion of FSH, while inhibins A and B suppress
its secretion.10 Another protein, follistatin, also acts to suppress FSH by binding to
activins depressing their secretion of the hormone. The menopausal transition introduces
changes in the regulation and levels of these proteins and hormones. A deficiency in
inhibin B first, followed by inhibin A, stimulates the initial (monotropic) rise in FSH
levels.12,17 A decrease in estradiol levels from the ovaries also contributes to the increased
levels of FSH in postmenopausal women.11,12 Estrogens continue to be produced by
extragonadal tissues, such as adipose tissue, however not in a comparable amount to that
produced prior to menopause.
While the main role of FSH relates to reproductive function, recent research has
shown that FSH receptor (FSHR) activity also occurs in extragonadal tissues.18-22 FSHR
has been expressed in the pancreas,18 osteoclasts,19 and the liver.20 These alternate
locations of FSH and FSHR suggest that the role of the hormone may not be strictly
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reproductive. Higher levels of FSH in postmenopausal women have been associated with
reduced risk of cardiovascular disease,23 obesity,24-27 and type 2 diabetes.28
Pathophysiology of Depression
There are a variety of factors that can lead to depression. Genetic influences may
contribute to the onset of depression. This likely involves the combination of genetic and
environmental factors, although many genes have been identified as potential
mechanisms of depressive symptoms.29 The main biochemical pathway that has been
determined in the etiology of depression involves monoamine neurotransmitters.29,30
Neurotransmitters are chemicals that are responsible for carrying signals from one neuron
to another across a synapse. This process begins with amino acids traveling to the brain
through the bloodstream, which trigger the conversion of precursor elements to become
neurotransmitters. Neurotransmitters are then stored in vesicles and released into the
synaptic cleft.
Cholesterol is essential for synaptic transmission as it is found in plasma
membranes and is used in the formation of various components of the neurotransmitter
pathway. Lower cholesterol levels can lead to decreased firing of neurotransmitters.31,32
Medical conditions and drugs can modify the rate of release into the synaptic cleft.
Serotonin (5-HT), norepinephrine, or dopamine are monoamine neurotransmitters that
influence a wide range of brain functions including mood, sleep, appetite, and cognition.
Deficiencies of these neurotransmitters in the central nervous system (CNS) have been
linked to increased rates of depression (the monoamine-deficiency theory). This
mechanism of depression is further supported by the efficacy of many antidepressants
which target the monoamine system.33
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Serotonin is the most extensively researched of the monoamines in the depression
pathway. Relationships between estradiol and serotonin have been established in prior
literature.34,35 One mechanism by which estradiol increases serotonin is through increased
production of tryptophan hydroxylase (TPH), which is the limiting factor in converting
tryptophan to serotonin.36 Estradiol inhibits the serotonin reuptake transporter (SERT)
which allows serotonin to remain in the body for longer amounts of time. Estradiol also
enhances the binding capabilities of serotonin receptors 5HT1A and 5HT2A.36,37 Decreased
estrogen during the menopausal transition may contribute to both vasomotor and
depressive symptoms as a result of decreased serotonin in the body.37 However, this
mechanism may be different in postmenopausal women. One study conducted by
Haliloglu et al. found an inverse relationship between estrogens and serotonin in a
postmenopausal population.38 It is suggested that an increase in serotonin is a
compensatory mechanism in response to cessation of estrogen production during the
menopausal transition, however research on this pathway is lacking. Because FSH
increases in postmenopausal women, in part, due to discontinued negative feedback from
estradiol, the mechanism that relates estrogens to serotonin may also influence FSH
levels.
Stress can also contribute to depression. When exposed to psychological stress,
the hypothalamus produces corticotropin-releasing hormone (CRH), which ultimately
releases cortisol into the body.30 Altered CRH pathways have been associated with major
depressive disorder (MDD). Stressors tend to influence people differently based on
gender, and women tend to have a higher sensitivity to overall stress.29,30 Structural
modification of components of the brain may contribute to stress sensitivity. Untreated
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depression has been associated with decreased volume of the hippocampus.39 This may
contribute to decreased ability to handle stress and the recurrence of depression.40
Exposure to stressful situations can also stimulate an inflammatory response in the body
by increased plasma cytokine levels. Experiments that administered interleukin-1 (IL-1),
IL-2, and interferon-𝛼𝛼 have resulted in stress-like response and depressive symptoms.29,41
Certain cytokines directly influence the body’s serotonin response; for example, IL-1 is a
regulator of the 5-HT transporter gene.30,41 Activins and follistatin (both regulators of
FSH) have been connected to inflammatory mechanisms.42 Furthermore, FSH has been
inversely associated with cytokine activity as well as intima-media thickness (IMT).43-45
Body composition, such as increased adiposity, may influence hormone
regulation contributing to depressive symptoms in postmenopausal women. Estrogens are
primarily produced by the ovaries prior to menopause; however, after menopause,
estrogens are produced by extragonadal tissue including adipose tissue. Higher estrogen
levels have been found in obese postmenopausal women compared to normal weight
postmenopausal women.46 These increased estrogen levels trigger the negative feedback
loop lowering FSH levels in the body. In a randomized study conducted by Kim et al.,
overweight, postmenopausal women were randomly assigned to one of three intervention
groups for one year with the goal of losing weight. Decreases in weight and BMI resulted
in increased levels of FSH after adjusting for estradiol.25 Observational studies have
found the same association.24,26 Furthermore, direct associations between obesity and
depression have been reported in postmenopausal women.46-48 A study conducted by
Chedraui et al. found that abdominal obesity (waist circumference >88 cm) was
associated with a 60% increased risk of depression (OR 1.6, 95% CI 1.0, 2.6).46 In a study
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conducted by Pan et al. showed that, compared to normal weight women, obese women
were 11% more likely to experience depression (OR 1.11, 95% CI 1.03, 1.18) after full
adjustment.48
Lipid profiles also change in the menopausal transition. Compared to
premenopausal women, postmenopausal women tend to have higher total cholesterol,
triglycerides, low density lipoprotein (LDL) levels, and very low density lipoprotein
(VLDL) levels, while high density lipoprotein (HDL) levels are lower.49-51 One study,
conducted by Persons et al., found an association between LDL-c levels below 100
mg/dL and depressive symptoms in postmenopausal women.52 These findings are
consistent with other studies that have found an inverse relationship between cholesterol
and depression.49,50 In a study of 400 postmenopausal women, Song et al. reported
decreased levels of FSH after administering estradiol treatment.20 This further resulted in
decreased levels of total cholesterol and LDL-c, independent of BMI. Additional analyses
in this study found evidence that FSH levels may inhibit LDL receptor expression. A
study conducted by Bertone-Johnson et al. found that total cholesterol and HDL levels
were higher in women of higher FSH levels, while triglycerides tended to be lower.43
Cholesterol profiles are important in the regulation of neurotransmitter function.
Decreased cholesterol levels limit the ability of neurotransmitter (e.g. serotonin) firing
contributing to depressive symptoms.29,30
FSH may be associated with these mechanisms of depression primarily through
its relationship with estrogens. Because the aforementioned depression pathways are
influenced by estrogen levels and FSH is regulated by a estrogen-mediated negative
feedback loop, FSH levels may also be associated with depression.
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CHAPTER III
EPIDEMIOLOGY OF FOLLICLE STIMULATING HORMONE AND DEPRESSION
Four cohort studies have explored the association between FSH and depression in
postmenopausal women.55-58 Bromberger at al. assessed the change in reproductive
hormones and depressive symptoms in 3,296 women aged 42 to 52 years enrolled in the
Study of Women’s Health Across the Nation (SWAN) Study.55 Data for this study were
collected annually from baseline (December 1995) to January 2008. Depressive
symptoms were assessed using the Center for Epidemiological Studies Depression (CESD) Scale (scores of 16 or higher identified depression). Fasting blood samples were used
to assess hormone levels (estradiol, FSH, testosterone, dehydroepiandrosterone sulfate
(DHEA-S), free estradiol index, and free testosterone index). These samples were
collected within 90 days of the anniversary of the baseline examination. Women were
considered postmenopausal if bleeding had not occurred within the previous 12 months;
four categories were determined: premenopausal, early perimenopausal, late
perimenopausal, postmenopausal. Covariates assessed were age, race/ethnicity, education
level, BMI, smoking status (current vs. not), medication for nerves or depression,
vasomotor symptoms, social support (score ranged from 0 to 16), and upsetting life
events (categorized as 0,1 or ≥2 very upsetting events). No association was found
between FSH levels and depressive symptoms in women regardless of menopause status
(logFSH OR = 1.05, 95% CI 0.97, 1.13).
Freeman et al. looked at this association in 203 late-reproductive age women who
were not using hormone therapy followed through the menopausal transition from the
Penn Ovarian Aging Study (POAS).56 During the 14-year follow-up of the study, all
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participants reached natural menopause. Depression was assessed using the CES-D in
which 16 or greater was determined as a high depressive symptom score. Follow-up
assessments were conducted approximately 9 months apart for the first five years, then
annually for the rest of the study. The timing of these visits was based on the early
follicular phase of the menstrual cycle for cycling women. Two visits were scheduled for
two consecutive menstrual cycles. For non-cycling women, these two visits occurred
approximately one month apart. At these assessments, blood samples were obtained to
assess hormone levels. Covariates assessed were history of depression, race, age, BMI,
current smoking status at the final menstrual period. Postmenopausal women were
identified as those who had not bled in the last 12 months. Current medication use
(including antidepressants) was also assessed. This study did not report an association
between absolute levels of FSH and risk of depression, but found that rates of change of
FSH levels prior to the final menstrual period were predictors of depression in
postmenopausal women. Specifically, higher rates of change of FSH levels over the span
of 4 years were associated with decreased depressive symptoms postmenopause (OR =
0.65, 95% CI 0.46-0.91).
Ryan et al. assessed the relationship of endogenous hormones and depressive
symptoms in 138 postmenopausal women from the Melbourne Women’s Midlife Health
Project (MWMHP).57 This analysis utilized data from years 11 and 13 of the full
MWMHP study. The average age of women at year 11 was 60.1 years (range 55.9-66.8
years). Women were determined postmenopausal if they had not bled in the last 12
months. Depressive symptoms were assessed using a shortened version of the CES-D (10
items) that contained questions concerning mood for the week prior. Scores were
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summed for a maximum score of 30; a cutoff of 10 was used to identify clinical
depression. Fasting morning blood samples were used to assess hormone levels. All
hormones (sex hormone binding globulin (SHBG), free androgen, FSH, testosterone, and
estradiol) were measured in year 11, but only FSH and estradiol were measured in year
13. Covariates assessed were age, BMI, level of education, living arrangement, and
employment status, alcohol consumption (for the past week), and smoking status (current
or past), and level of current physical activity. The following chronic health conditions
were also assessed: high cholesterol (total cholesterol, HDL, LDL), diabetes,
hypertension, chronic asthma, heart disease, stomach or bowel ulcers, arthritis,
rheumatism, cancer, and migraine. Information for medications for these conditions was
also obtained. The presence of 22 common symptoms (e.g. dizzy spells, headaches, lack
of energy, etc.) in the two weeks prior were assessed using a shortened daily hassles
scale. Women’s attitudes towards menopause using an 8-item questionnaire were
assessed. Absolute values of FSH and estradiol were not associated with depression in
either year. Compared to women with FSH levels less than 70 IU/l, women with FSH
levels at or above this threshold had an odds ratio of 0.78 (95% CI 0.33, 1.82) of
depression (year 11). Compared to women with FSH levels less than 80 IU/l, women
with FSH levels at or above this threshold had an odds ratio of 1.39 (95% CI 0.59, 3.26)
of depression (year 13). This study, however, did find statistically significant results in
the association between change in FSH over the 2-year period and risk of depression. A
9+ IU/l increase in FSH levels was associated with a 2.57 increased odds of developing
depressive symptoms (95% CI 1.0-6.69, p=0.05). Similarly, decreases in estradiol were
associated with increased depression risk.
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Woods at al. assessed this relationship in 302 women from the Seattle Midlife
Women’s Health Study (SMWHS).58 Postmenopause was determined as 12 months
without bleeding. Depression was measured using the CES-D for which 16 was
determined to be the cutoff score for depression. A total of 87 postmenopausal women
(obs = 319) provided data for this study. A first-voided morning urine sample was
collected on a consistent date each month (for women with no bleeding) to measure
hormone levels (estrone glucuronide, FSH, testosterone, cortisol, and creatinine).
Covariates assessed through information obtained through questionnaires were history of
sexual abuse and postpartum blues, live births, family history of depression, negative life
event stress, hot flashes, BMI, and use of antidepressants. No association was found
between FSH and depressed mood (numerical results were not included in the article).
In summary, two of these studies found no association between FSH levels and
depressive symptoms or depression in postmenopausal women. One of the studies found
a change in FSH levels over time is associated with depression. One study found rate of
change of FSH prior to the final menstrual cycle was inversely related to depression
outcome postmenopause. All four studies found no association between estradiol and
depression. None of the studies included women who were using hormone therapy,
similar to our study. These studies have provided a foundation for the research on FSH
and depression in postmenopausal women. One gap in research that needs to be filled is
the assessment of the relationship of FSH and depression in older postmenopausal
women. The recruitment of pre- or perimenopausal women at baseline limits the
generalizability of results to women who have been postmenopause for many years as
hormone levels may vary as time since menopause increases.
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While the studies with women of different menopausal status did attempt to look
at FSH and depression in postmenopausal women as a component of their analyses, their
results were difficult to interpret and may have suffered from misclassification. Two of
the studies also had smaller sample sizes (n=203; n=138) which may limit the power of
observed associations.56,57 These two studies did not find associations between absolute
hormone levels and depression, but rather associations between (rate of) change of
hormone levels and depression. This may be a result of residual hormone fluctuations
following menopause and may possibly only apply to postmenopausal women who have
recently completely the transition. One study did not collect information on
antidepressant use57 which may have attenuated results. Findings that describe the
relationship between FSH and depression in women of all menopausal stages (pre-, peri-,
and postmenopausal), lack of data on older postmenopausal women, and small sample
sizes leaves the relationship of FSH and depression in postmenopausal women not well
understood.
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CHAPTER IV
SUMMARY AND PROPOSED RESEARCH
The population we had data on represented a wide age range of postmenopausal
women, some of which completed the transition many years prior to data collection. This
is novel in that prior studies only evaluated women shortly after the menopausal
transition. Because hormone levels may be different in women as a result of time since
menopause, data on older postmenopausal women is pertinent. We also had access to a
wide range of covariates for which we were able to adjust. The goals for our analysis
were to examine the relationship between FSH and depression and depressive symptoms
in an older postmenopausal population. We also stratified based on age and BMI to
assess possible effect modification by these variables.
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CHAPTER V
HYPOTHESES AND SPECIFIC AIM
Specific Aim:
Using data from the Kuopio Ischaemic Heart Disease Risk Factor Study, we evaluated
the relationship between levels of follicle stimulating hormone (FSH) and depressive
symptoms and depression in postmenopausal women.
Hypothesis 1:
There will be an inverse association between FSH levels and depressive
symptoms.
Hypothesis 2:
There will be an inverse association between FSH levels and prevalence of
depression.
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CHAPTER VI
METHODS
Study Design and Population
We assessed the relationship between FSH levels and depressive symptoms and
depression in postmenopausal women using data from the Kuopio Ischaemic Heart
Disease Risk Factor (KIHD) Study. The KIHD Study is an ongoing, population-based
prospective cohort study that began in 1984, originally enrolling exclusively male
participants to investigate risk factors for cardiovascular disease in Eastern Finland.59
Female participants who had completed the menopausal transition were first enrolled in
March 1998. Baseline examinations for women were conducted between March 1998 and
February 2001 and included information on dietary intake, biochemical measures,
neuropathological tests, and other risk factors. The proposed study will be cross-sectional
using baseline data from 1998-2001.
Eligible women were postmenopausal women who enrolled in the KIHD Study
between March 1998 and February 2001. Postmenopausal status was defined by the
absence of menses for at least 12 months, or at time of oophorectomy for women
reporting surgery prior to menopause. Women eligible for enrollment in the KIHD Study
were a random sample (n = 1173) living the city of Kuopio and surrounding rural
communities during this time, and women in four specific age groups were targeted: 5356, 59-62, 64-68, and 71-73 years. Of eligible women, 920 completed baseline clinical
assessments and joined the cohort (78.4%). For the purpose of the proposed study,
women who were missing data on FSH and/or depression were excluded (n = 7). Women
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who were using hormone therapy at baseline were also excluded due to the influence
hormone therapy has on FSH levels (n = 325).
Assessment of FSH
During the baseline examination, fasting blood samples were collected between 8
am and 10 am. Participants were asked to abstain from eating or smoking cigarettes for
12 hours prior to the examination and alcohol for three days prior. Plasma was separated
from other blood components within 60 minutes of collection and stored at -20°C or 80°C until assay. Samples were assayed for FSH between June 2001 and February 2002.
A sandwich technique was used which applied an immunoradiometric assay
manufactured by Diagnostic Product Corporation (Coat-A-Count FSH IRMA; Los
Angeles, CA). 125 I label measurements for FSH were carried out by gamma counter
Wallac 1261 MultiGamma using a RiaCalc LM Evaluation Program. FSH levels in our
data will be analyzed both categorically by quartiles and continuously. For quality
control, triplicates of low, medium, and high Lyphochek controls were included in each
run. Coefficients of variation were 5% for each set of controls.
Assessment of Depression
The DSM-12D was used to assess depressive symptoms in this study. This scale
contained 12 questions for which participants answered yes or no to experiencing the
presented symptoms nearly every day for the past two weeks. Symptoms assessed
included sadness, feelings of worthlessness, difficulties in concentrating, variation of
eating patterns (too much or too little), issues with sleeping (sleeping too much or trouble
sleeping), and thoughts about death. This scale was developed using criteria similar to
those from the DSM-IV. A cutoff score of 5 and greater identified depression for
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analyses using a dichotomous outcome. This cutoff has been used in prior studies.60,61
Antidepressant use was also used as a proxy for depression in secondary analysis. In this
analysis, we included antidepressant users as cases regardless of symptom score, as well
as excluding them from our models to assess their possible influence on our results.
Covariate Assessment
Clinical Measures
At a clinical interview, height and weight were directly measured and used to
calculate body mass index (BMI; weight in kg/ht in m2). Waist and hip circumferences
were measured with a standard measuring tape in order to calculate waist-to-hip ratios.
Blood Collection and Biochemical Measurements
In addition to FSH, estradiol, testosterone, and sex hormone binding globulin
(SHBG) samples were also assayed using the blood samples mentioned prior. Serum 17𝛽𝛽-estradiol was assayed between 1999 and 2001 with a radioimmunoassay manufactured

by DiaSorin (Stillwater, MN). Four different types of controls were included in each run:
Lyphochek low and medium controls, in-house serum pool, and a control provided by the
kit manufacturer. Concentrations of 17-𝛽𝛽-estradiol were in the physiologic range for the
in-house pool, and higher for other control types. Coefficients of variation ranged from
7.6% (in-house pool) to 12.0% (manufacturer control). Serum testosterone (17𝛽𝛽-hydroxy4-androsten-3-one) was determined with Spectria Testosterone [125I] radioimmunoassay
kit (Orion Diagnostica Espoo, Finland). In each assay were included three different
controls: Lyphocheck low, medium, and high. Coefficients of variation ranged from 7.9%
(high control) to 12.2% (low control). 125I label measurements of estradiol and
testosterone were carried out by gamma counter Wallac 1261 MultiGamma using a
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RiaCalc LM Evaluation Program. Sex hormone binding globulin (SHBG) was evaluated
using the 1235 AutoDELFIA automatic system based on a time-resolved
fluoroimmunoassay (AutoDELFIA SHBG, Wallac, Turku, Finland).62
Samples from all participants were assayed for total, HDL and LDL cholesterol,
and triglycerides using laboratory methods described in detail previously. Cholesterol
contents of lipoprotein fractions and serum triglycerides were measured enzymatically;
HDL fractions were separated from serum by combined ultracentrifugation and
precipitation.63 Coefficients of variation were 2.3% for total cholesterol, 5.2% for LDL,
9.2% for HDL, and 1.9% for triglycerides.
Questionnaire Assessments
Participants in the KIHD Study completed questionnaires that included
information on demographic, behavioral, reproductive, and health-related variables which
were reviewed by trained interviewers for completeness and clarity. Covariates
considered from the questionnaires included age, cigarette use (never, ever, current),
antidepressant use, presence of other chronic diseases, education, marital status, and
physical activity levels (MET hours/week). A detailed alcohol use questionnaire was used
to determine alcohol intake (grams/week).64 Physical activity was determined using the
KIHD 12-Month Leisure Time Physical Activity Questionnaire, which was used to
estimate metabolic equivalent of task hours of activity per day.65 Reproductive factors
considered were age at menarche, age at menopause, number of full term pregnancies,
prior use of hormone therapy (including duration), and use of oral contraceptives. Age at
menopause was determined using the criteria for postmenopausal (mentioned prior).
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Study physicians conducted interviews to obtain information on use of
medications for hypertension, diabetes, heart disease, angina pectoralis, and high
cholesterol.65
Statistical Analysis
Specific Aim 1:
Using data from the Kuopio Ischaemic Heart Disease Risk Factor Study, we propose to
evaluate the relationship between levels of follicle stimulating hormone (FSH) and
depressive symptoms and depression in postmenopausal women.
Univariate Analysis
The study population size after accounting for exclusion criteria (missing data on
FSH or depressive symptoms) who were not using hormone therapy was n=588.
Bivariate Analysis
Covariate relationships were compared across quartiles of FSH levels (Table 1).
Continuous covariates were assessed using t-tests. Categorical covariates were assessed
using chi-square tests. We assessed the association between FSH levels and depression
(dichotomous) using logistic regression (Table 2) and the association between FSH levels
and depressive symptom score (continuous) using linear regression (Table 3). P values
from all tests were reported. Odds ratios and 95% CIs were reported.
Multivariable Analysis
Multivariable logistic regression was used to analyze the association between
FSH and depression. FSH was assessed both continuously and dichotomously, dividing
FSH levels at the median (50 IU/L, high vs. low). Model 1 adjusted for age. Model 2
used forward building to create the most parsimonious model representing the association
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between FSH and depression. The covariates included in this model were age, BMI,
waist-to-hip ratio, and estradiol. Other covariates tested for inclusion were identified
from the existing literature 2, 55-58, 66,67 but not included were smoking status, alcohol
consumption, past hormone therapy use and duration, oral contraceptive use, presence of
other chronic diseases, physical activity levels, level of education, marital status,
employment status, age at menarche, parity, age at menopause, and levels of testosterone
and SHBG. Covariates were retained in the final model if they had a P value less than
0.10 using a likelihood ratio test or if their inclusion let to a change in the beta coefficient
of the FSH-depression relationship greater than or equal to 10%.
Multivariable linear regression was used to analyze the association between FSH
and depressive symptom scores. FSH was assessed both continuously and by quartiles in
linear models. Model 1 assessed the relationship between FSH and depressive symptoms
adjusting for age, date of examination (year), and estradiol (quartiles). Model 2 included
model 1 variables with further adjustment for BMI and waist to hip ratio. Model 3
included model 2 variables with further adjustment for employment status, marital status,
education level, physical activity, past hormone use and duration, smoking status, alcohol
consumption, parity, age at menopause, testosterone, and SHBG. Linear trends across
quartiles of FSH were assessed by modeling the median value of each quartile as a
continuous variable. Despite a non-normal distribution, we left depressive symptom score
untransformed for purposes of interpretation. Trends were the same in transformed and
untransformed models.
Models stratifying by BMI (normal/underweight, overweight, obese) and age
were also created to assess possible effect modification. These models were assessed with
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multiplicative interaction terms, and likelihood ratio test P < 0.05 was considered
significant. In secondary analysis, we assessed the relationship between FSH and
depression while including women taking antidepressants as cases for depression
regardless of symptom score (Table 8). We also assessed the relationship excluding
antidepressant users (Table 9). Statistical analyses were completed with Stata/IC 15.1 for
Mac (StataCorp LLC).
Sample Size and Power Calculations
The sample size for our study was n=588. High FSH and low FSH groups were
created by dividing the sample size at the median of FSH (50.0 IU/L) resulting in a nearly
1:1 ratio. Post hoc power calculations using G Power indicate we had the ability to detect
an odds ratio of 0.71 with 80% power for prevalent depression comparing women with
high FSH levels to women of low FSH levels. Among quartiles of FSH, we are able to
detect an effect size of 0.13 of FSH quartile on depressive symptom score with 80%
power.
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CHAPTER VII
RESULTS
Characteristics of participants by quartiles of FSH are presented in Table 1.
Women in the highest quartile of FSH were younger and had a lower BMI and waist-tohip ratios than women in the lowest quartile of FSH. Estradiol was higher in quartile 1 of
FSH than quartiles 2 to 4. FSH levels were inversely related to parity, but not related to
age at menarche or age at menopause. Women with higher FSH were more likely to
report the use of medication for hypertension, heart disease, diabetes, and angina
pectoralis than women with lower FSH levels. The distribution of other factors did not
differ significantly across quartiles of FSH. Most women had depressive symptom scores
of 0 and 1 on the scale (n = 285). Based on the cut off score of 5 for probable depression,
61 women were considered depressed.
As shown in Table 2, FSH was inversely related to the prevalence of depression
when adjusting for age (OR = 0.45, 95% CI 0.25, 0.79; model 1). Additional adjustment
for BMI, WHR, and estradiol (model 2) attenuated results slightly, but they remained
statistically significant; women with FSH levels above the median had an OR for
prevalent depression of 0.50 (95% CI 0.28, 0.89) compared to women with FSH levels
below the median. Assessing the relationship between continuous FSH levels and
depression showed that every 10-unit increase in FSH was associated with a 17%
decrease in prevalence of depression (OR 0.83, 95% CI 0.70 – 0.99, P=0.04).
Results from multivariable linear regression models assessing the association of
quartiles of FSH and depressive symptom score are shown in Table 3. Mean depressive
symptom scores of women in quartiles 1 through 4 of FSH were 2.2, 2.0, 1.8, and 1.4,
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respectively (P = 0.01). FSH was inversely associated with depressive symptom score in
models adjusting for age, examination date, and levels of E2 (model 1; P for trend =
0.001) and adiposity measures (model 2; P for trend = 0.002). Full adjustment (model 3)
resulted in beta coefficients of 0.186, -0.129, -0.478 for quartiles 2 through 4 of FSH,
respectively, however this relationship was not statistically significant (P for trend =
0.15).
To determine if the association of FSH and depression varied by age, we stratified
by age group (ages 53-62 years vs. 64-73 years; Tables 4 and 5). The association of
higher vs. lower FSH and depression was similar in older and younger women (P for
interaction = 0.87). In older women, each 10-unit increase in FSH was associated with a
26% lower prevalence of depression (OR = 0.74, 95% CI 0.57-0.95, P = 0.02), though
this linear relation was not observed in younger women (OR = 0.96, 95% CI 0.75-1.22; P
for interaction = 0.20).
In analysis of depressive symptom score, similar results to assessing dichotomous
outcome were obtained. In younger postmenopausal women, beta coefficients were
0.384, 0.646, and 0.664 across quartiles 2 through 4 of FSH, respectively (P for trend =
0.26). The beta coefficients for older postmenopausal women -0.345, -0.948, -1.374 (P
for trend = 0.02; P for interaction = 0.44).
We also stratified according to WHO categories of BMI (<25.0, 25.0 - 29.9, ≥30.0
kg/m2; Tables 6 and 7). We observed a lower prevalence of depression with high FSH
levels in normal weight and overweight women, but not in obese women (P for
interaction = 0.11). In the normal weight group, an OR of 0.19 (95% CI 0.03-1.36) was
observed; in the overweight group, an OR of 0.33 (95% CI 0.14-0.81); and in the obese
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group, an OR of 0.90 (95% CI 0.38-2.15). In analyses of depressive symptom score, nonlinear trends were observed across quartiles of FSH for normal and obese groups.
In secondary analysis, including antidepressant users as cases resulting in an
attenuation of our results, however the observed trends persisted (Table 8). We observed
a lower prevalence of depression in women with higher FSH levels (OR = 0.62, 95% CI
0.37, 1.04). When antidepressant users were excluded in linear models (Table 9), beta
coefficients of 0.150, -0.236, -0.604 (P for trend = 0.09) were observed for quartiles 2
through 4 of FSH, respectively.
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CHAPTER VIII
DISCUSSION
We observed significant inverse associations between FSH levels and depression
and depressive symptoms among postmenopausal women. This trend was more
pronounced in older postmenopausal women (ages 64-73 years). Effect modification by
age and BMI was suggested by our results despite non-significant observed interaction.
Prior studies have not assessed this relationship in older postmenopausal women, which
is apparent by the enrollment of predominantly pre- or peri-menopausal women in
studies. Of the four studies that have assessed this association in postmenopausal women,
none found associations between absolute levels of FSH and depression. Two prior
studies have found that rates of change in FSH levels are associated with depression,
however, the application of this association may only be relevant to women going
through the menopausal transition or early postmenopausal women as these are the time
periods in which large hormone fluctuations typically occur. Furthermore, one of the
studies evaluated rates of change in hormone levels prior to the onset of menopause
which may not be applicable to older postmenopausal women.
Our study had a few limitations. Because our study is cross sectional, we cannot
evaluate the temporality of the relationship between FSH and depression. The population
enrolled in the KIHD Study is very homogenous with respect to race and ethnicity
limiting the generalizability to other races if pathways between FSH and depression are
dependant on race or ethnicity. Nondifferential misclassification of the outcome could
have occurred as depression is a cyclic disease, and women may not have been
experiencing depressive symptoms at the time of the assessment. Had this occurred, it
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would have attenuated our results. We had data on many variables for which we were
able to control for, but potential confounders may have not been evaluated. Because
research on this association is relatively novel, possible influential factors have not been
established. Additionally, we did not have information on history of depression.
Assessing the the relationship between FSH and depression based on prior depressive
episodes may have provided alternate results. Evaluating the relationship of FSH and
depression in studies including more diverse populations should be a goal of future
research. Strengths of our study include access to extensive data on covariate measures to
adequately assess potential confounding relationships and effect modification. We also
had data on women of many ages allowing our results to be likely generalizable to all
postmenopausal women not using hormone therapy.
To our knowledge, this is the first study to assess the association between FSH
and depression and depressive symptoms in older postmenopausal women, for which
hormone levels may be different compared to younger postmenopausal women. We
observed evidence of lower prevalence of depression for women with higher FSH levels,
which was not explained by confounding factors such as estradiol and adiposity
measures. Future steps should focus on absolute hormone levels in postmenopausal
women of all ages (rather than focusing primarily on early postmenopausal women) and
how these measures relate to depressive symptoms. Understanding the biochemical and
inflammatory mechanisms involved with this relationship and how they might change as
postmenopausal women age is another important step for future research.

26

Table 1. Characteristics of Women not Using Hormone Therapy by Quartile of Follicle
Stimulating Hormone, Kuopio Ischaemic Heart Disease Risk Factor Study, 1998-2001.
Quartile 1
Quartile 2
Quartile 3
Quartile 4
FSH Ranges (IU/L)
1-39.3
39.4-50.0
50.1-61.8
61.9-150
n
147
149
145
147
M (SD)
M (SD)
M (SD)
M (SD)
Age, y
64.5 (6.8)
65.1 (5.9)
64.4 (6.1)
62.9 (6.9)
Body Mass Index (kg/m2)
31.1 (5.7)
29.0 (5.4)
28.8 (5.0)
26.8 (4.4)
Waist:hip ratio
0.87 (0.07) 0.85 (0.06) 0.84 (0.06) 0.83 (0.06)
Estradiol, pmol/L
55.8 (77.6) 35.1 (19.8) 32.5 (12.5) 34.1 (19.5)
Testosterone, nmol/L
1.5 (2.9)
1.1 (0.5)
1.1 (0.5)
1.1 (0.5)
Sex-hormone binding
45.5 (23.0) 49.5 (21.2) 55.0 (24.3) 58.2 (27.7)
globulin, nmol/L
Alcohol consumption, g/wk 15.4 (32.2) 23.6 (53.2) 15.2 (29.4) 13.6 (26.0)
Exercise, MET h/d
45.2 (5.8)
46.0 (7.0)
46.3 (6.1)
47.3 (7.4)
Age at menarche, y
13.7 (1.6)
13.9 (1.4)
14.1 (1.5) 13.9 (1.6)
Age at menopause, y
49.8 (4.3)
49.5 (4.3)
48.9 (4.7)
49.3 (4.2)
Parity, full term
2.5 (1.6)
2.4 (1.8)
2.5 (1.8)
2.0 (1.5)
pregnancies
Past hormone therapy
2.0 (1.2)
2.0 (1.3)
2.0 (1.0)
2.6 (1.4)
duration, y

Smoking status
Never
Former
Current
Oral contraceptive use
Never
Former
Past hormone therapy use
Marital Status
Married/Living as
couple
Not married
Separated/Divorced
Widowed
Employment status
Retired
Employed full time
Employed part time
Unemployed

N (%)

N (%)

N (%)

N (%)

116 (78.9)
19 (12.9)
12 (8.2)

120 (80.5)
15 (10.1)
14 (9.4)

118 (81.4)
11 (7.6)
16 (11.0)

121 (82.3)
19 (12.9)
7 (4.8)

106 (72.1)
41 (27.9)
38 (25.9)

112 (75.2)
37 (24.8)
45 (30.2)

94 (64.8)
51 (35.2)
48 (33.1)

97 (66.0)
50 (34.0)
49 (33.3)

96 (64.4)

90 (62.1)

91 (61.9)

8 (5.4)
12 (8.2)
30 (20.4)

14 (9.4)
13 (8.7)
26 (17.5)

13 (9.0)
14 (9.7)
28 (19.3)

18 (12.2)
17 (11.6)
21 (14.3)

109 (74.2)
22 (15.0)
7 (4.8)
9 (6.1)

121 (81.2)
18 (12.1)
2 (1.3)
8 (5.4)

114 (78.6)
18 (12.4)
3 (2.1)
10 (6.9)

90 (61.2)
34 (23.1)
6 (4.1)
17 (11.6)

P Value
0.02
<0.001
<0.001
<0.001
0.06
<0.001
0.09
0.05
0.16
0.44
0.02
0.05
P Value
0.37

0.17

97 (66.0)

0.47
0.65

0.02
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Current medication usea
Antidepressants
Hypertension
Heart disease
High cholesterol
Diabetes
Angina
Education
Low
Low moderate
High moderate
High
a
Not mutually exclusive

N (%)

N (%)

N (%)

N (%)

P Value

7 (4.8)
83 (56.5)
27 (18.4)
5 (3.4)
14 (9.5)
25 (17.0)

4 (2.7)
77 (51.7)
20 (13.4)
11 (7.4)
6 (4.0)
18 (12.1)

7 (4.8)
63 (43.5)
13 (9.0)
7 (4.8)
6 (4.1)
12 (8.3)

5 (3.4)
51 (34.7)
11 (7.5)
4 (2.7)
2 (1.4)
7 (4.8)

0.73
0.001
0.02
0.23
0.01
0.01
0.6

19 (12.9)
48 (32.7)
64 (43.5)
16 (10.9)

13 (8.7)
50 (33.6)
71 (41.7)
15 (10.1)

10 (6.9)
58 (40.0)
64 (44.1)
13 (9.0)

13 (8.8)
44 (29.9)
77 (52.4)
13 (8.8)

28

29

30

31

32

33

34
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